163 related articles for article (PubMed ID: 35612637)
1. Factors associated with 1-year changes in serum fibroblast growth factor 23 levels in pediatric patients with chronic kidney disease.
Yamamura-Miyazaki N; Michigami T; Ozono K; Yamamoto K; Hasuike Y
Clin Exp Nephrol; 2022 Oct; 26(10):1014-1021. PubMed ID: 35612637
[TBL] [Abstract][Full Text] [Related]
2. Fibroblast growth factor 23 and new-onset chronic kidney disease in the general population: the Prevention of Renal and Vascular Endstage Disease (PREVEND) study.
De Jong MA; Eisenga MF; van Ballegooijen AJ; Beulens JWJ; Vervloet MG; Navis G; Gansevoort RT; Bakker SJL; De Borst MH
Nephrol Dial Transplant; 2021 Jan; 36(1):121-128. PubMed ID: 32124925
[TBL] [Abstract][Full Text] [Related]
3. Applicability of fibroblast growth factor 23 for evaluation of risk of vertebral fracture and chronic kidney disease-mineral bone disease in elderly chronic kidney disease patients.
Kanda E; Yoshida M; Sasaki S
BMC Nephrol; 2012 Sep; 13():122. PubMed ID: 23013306
[TBL] [Abstract][Full Text] [Related]
4. The FGF23-Klotho axis and cardiac tissue Doppler imaging in pediatric chronic kidney disease-a prospective cohort study.
Tranæus Lindblad Y; Olauson H; Vavilis G; Hammar U; Herthelius M; Axelsson J; Bárány P
Pediatr Nephrol; 2018 Jan; 33(1):147-157. PubMed ID: 28795324
[TBL] [Abstract][Full Text] [Related]
5. Associations of fibroblast growth factor 23, vitamin D and parathyroid hormone with 5-year outcomes in a prospective primary care cohort of people with chronic kidney disease stage 3.
Shardlow A; McIntyre NJ; Fluck RJ; McIntyre CW; Taal MW
BMJ Open; 2017 Aug; 7(8):e016528. PubMed ID: 28838895
[TBL] [Abstract][Full Text] [Related]
6. FGF23 as a Potential Pathophysiological Factor in Peripheral Arterial Disease Associated with Chronic Kidney Disease.
Donate-Correa J; Martín-Núñez E; Hernández-Carballo C; González-Luis A; Mora-Fernández C; Martín-Olivera A; Rodríguez-Ramos S; Cerro-López P; López-Castillo Á; Delgado-Molinos A; López-Tarruella VC; Navarro-González JF
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791495
[TBL] [Abstract][Full Text] [Related]
7. Fibroblast growth factor 23 and soluble klotho in children with chronic kidney disease.
Wan M; Smith C; Shah V; Gullet A; Wells D; Rees L; Shroff R
Nephrol Dial Transplant; 2013 Jan; 28(1):153-61. PubMed ID: 23180879
[TBL] [Abstract][Full Text] [Related]
8. Progression of arterial stiffness is associated with changes in bone mineral markers in advanced CKD.
Krishnasamy R; Tan SJ; Hawley CM; Johnson DW; Stanton T; Lee K; Mudge DW; Campbell S; Elder GJ; Toussaint ND; Isbel NM
BMC Nephrol; 2017 Sep; 18(1):281. PubMed ID: 28870151
[TBL] [Abstract][Full Text] [Related]
9. The influence of glomerular filtration rate and age on fibroblast growth factor 23 serum levels in pediatric chronic kidney disease.
Bacchetta J; Dubourg L; Harambat J; Ranchin B; Abou-Jaoude P; Arnaud S; Carlier MC; Richard M; Cochat P
J Clin Endocrinol Metab; 2010 Apr; 95(4):1741-8. PubMed ID: 20157196
[TBL] [Abstract][Full Text] [Related]
10. Inflammation and elevated levels of fibroblast growth factor 23 are independent risk factors for death in chronic kidney disease.
Munoz Mendoza J; Isakova T; Cai X; Bayes LY; Faul C; Scialla JJ; Lash JP; Chen J; He J; Navaneethan S; Negrea L; Rosas SE; Kretzler M; Nessel L; Xie D; Anderson AH; Raj DS; Wolf M;
Kidney Int; 2017 Mar; 91(3):711-719. PubMed ID: 28017325
[TBL] [Abstract][Full Text] [Related]
11. Secreted Klotho and FGF23 in chronic kidney disease Stage 1 to 5: a sequence suggested from a cross-sectional study.
Pavik I; Jaeger P; Ebner L; Wagner CA; Petzold K; Spichtig D; Poster D; Wüthrich RP; Russmann S; Serra AL
Nephrol Dial Transplant; 2013 Feb; 28(2):352-9. PubMed ID: 23129826
[TBL] [Abstract][Full Text] [Related]
12. The relationship between urinary kidney injury molecule-1 and blood bone metabolism markers in patients with chronic kidney disease
.
Yin C; Cheng C; Wang J; Zhang L; Purrunsing Y; Yang G; Zeng M; Huang H; Ren W; Ye Y; Ma H; Xing C; Wang N
Clin Nephrol; 2020 Feb; 93(2):65-76. PubMed ID: 31793871
[TBL] [Abstract][Full Text] [Related]
13. Disordered FGF23 and mineral metabolism in children with CKD.
Portale AA; Wolf M; Jüppner H; Messinger S; Kumar J; Wesseling-Perry K; Schwartz GJ; Furth SL; Warady BA; Salusky IB
Clin J Am Soc Nephrol; 2014 Feb; 9(2):344-53. PubMed ID: 24311704
[TBL] [Abstract][Full Text] [Related]
14. Phosphate, fibroblast growth factor 23 and retinopathy in chronic kidney disease: the Chronic Renal Insufficiency Cohort Study.
Mehta R; Ying GS; Houston S; Isakova T; Nessel L; Ojo A; Go A; Lash J; Kusek J; Grunwald J; Wolf M;
Nephrol Dial Transplant; 2015 Sep; 30(9):1534-41. PubMed ID: 25910495
[TBL] [Abstract][Full Text] [Related]
15. Tumor necrosis factor stimulates fibroblast growth factor 23 levels in chronic kidney disease and non-renal inflammation.
Egli-Spichtig D; Imenez Silva PH; Glaudemans B; Gehring N; Bettoni C; Zhang MYH; Pastor-Arroyo EM; Schönenberger D; Rajski M; Hoogewijs D; Knauf F; Misselwitz B; Frey-Wagner I; Rogler G; Ackermann D; Ponte B; Pruijm M; Leichtle A; Fiedler GM; Bochud M; Ballotta V; Hofmann S; Perwad F; Föller M; Lang F; Wenger RH; Frew I; Wagner CA
Kidney Int; 2019 Oct; 96(4):890-905. PubMed ID: 31301888
[TBL] [Abstract][Full Text] [Related]
16. Associations of Fibroblast Growth Factor 23 with Markers of Inflammation and Leukocyte Transmigration in Chronic Kidney Disease.
Wallquist C; Mansouri L; Norrbäck M; Hylander B; Jacobson SH; Larsson TE; Lundahl J
Nephron; 2018; 138(4):287-295. PubMed ID: 29301137
[TBL] [Abstract][Full Text] [Related]
17. Serum Fibroblast Growth Factor 23 Levels are Associated with Vascular Smooth Muscle Dysfunction in Type 2 Diabetes.
Natsuki Y; Morioka T; Kakutani Y; Yamazaki Y; Ochi A; Kurajoh M; Mori K; Imanishi Y; Shoji T; Inaba M; Emoto M
J Atheroscler Thromb; 2023 Dec; 30(12):1838-1848. PubMed ID: 37225519
[TBL] [Abstract][Full Text] [Related]
18. Intact FGF23 and α-Klotho during acute inflammation/sepsis in CKD patients.
Dounousi E; Torino C; Pizzini P; Cutrupi S; Panuccio V; D'Arrigo G; Abd ElHafeez S; Tripepi G; Mallamaci F; Zoccali C
Eur J Clin Invest; 2016 Mar; 46(3):234-41. PubMed ID: 26728476
[TBL] [Abstract][Full Text] [Related]
19. Serum levels of soluble secreted α-Klotho are decreased in the early stages of chronic kidney disease, making it a probable novel biomarker for early diagnosis.
Shimamura Y; Hamada K; Inoue K; Ogata K; Ishihara M; Kagawa T; Inoue M; Fujimoto S; Ikebe M; Yuasa K; Yamanaka S; Sugiura T; Terada Y
Clin Exp Nephrol; 2012 Oct; 16(5):722-9. PubMed ID: 22457086
[TBL] [Abstract][Full Text] [Related]
20. Association of fibroblast growth factor 23 and α-klotho in hemodialysis patients during administration of ferric citrate hydrate: post hoc analysis of ASTRIO study.
Ito K; Yokoyama K; Nakayama M; Fukagawa M; Hirakata H
BMC Nephrol; 2021 Nov; 22(1):374. PubMed ID: 34758731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
